What is HC Wainwright’s Forecast for KYTX FY2024 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Investment analysts at HC Wainwright dropped their FY2024 EPS estimates for Kyverna Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($3.14) for the year, down from their previous estimate of ($3.01). HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.77) EPS.

Several other research analysts also recently issued reports on KYTX. JPMorgan Chase & Co. cut their price target on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Wells Fargo & Company decreased their price objective on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, November 15th. UBS Group began coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 target price for the company. RODMAN&RENSHAW raised Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $25.71.

Kyverna Therapeutics Stock Down 3.2 %

Shares of NASDAQ KYTX opened at $3.99 on Friday. The stock has a fifty day moving average price of $5.28 and a 200 day moving average price of $8.24. Kyverna Therapeutics has a 1-year low of $3.94 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of hedge funds have recently made changes to their positions in KYTX. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Kyverna Therapeutics during the 1st quarter worth approximately $78,590,000. Novo Holdings A S grew its stake in Kyverna Therapeutics by 150.0% in the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock valued at $13,125,000 after purchasing an additional 1,050,000 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Kyverna Therapeutics during the first quarter worth $23,093,000. Janus Henderson Group PLC bought a new stake in shares of Kyverna Therapeutics in the 1st quarter valued at about $15,041,000. Finally, Deerfield Management Company L.P. Series C lifted its holdings in Kyverna Therapeutics by 35.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after purchasing an additional 520,663 shares during the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.